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Abstract 
Introduction: - Plasmodium vivax accounts for about 40% of all malaria infection in Ethiopia. Chloroquine 
remains the drug of choice for the treatment of p.vivax malaria in the country. Emerging resistance to 
chloroquine (CQ) by P.vivax threatens the health of the hundreds of thousands of people regularly exposed to the 
risk of infection with this organism. There was 14 years back failure alarm report of P.vivax to chloroquine but 
there has been no research in Jimma town which show extent of efficacy of medication. Therefore this study 
designed to assess the therapeutic efficacy of chloroquine used in the treatment of P.vivax malaria infection at 
health centers in Jimma town South West Ethiopia.Methods: An in vivo prospective drug efficacy study was 
conducted in Jimma town from February10 to May 09, 2011. Eight one Patients with microscopically confirmed 
P. vivax malaria, aged between 6 months and 60 years, were recruited and treated under supervision with 
Chloroquine (10mg/kg at 0 and 24 hrs followed by 5mg/kg at 48 hrs orally). Clinical and parasitological 
parameters were assessed during the 28 day follow-up period as per with methods for surveillance of 
antimalarial drug efficacy WHO 2009. Data was analyzed using SPSS, version 16.0.Results: Of the total 81 
patients included in the study, 74 completed their 28-day follow-up. Despite of the 100% clearance of both fever 
and parasitemia on day 3, parasitaemia reappeared in two participants within the 28-days follow-up with the 
absence of malaria symptoms. Therefore, the cumulative incidence of treatment failure was 2.7% (with 95%CI -
0.99 - 6.39) in study participants. Conclusions: chloroquine is still now efficacious drug to P.vivax in study area. 
However, reappearance of the parasite within the 28 days of follow-up in the study area signals the need for 
launching monitory activities for Chloroquine resistant by the P. vivax parasite.  
Keywords: malaria, p.vivax, chloroquine, therapeutic efficacy, Jimma. 
 
INTRODUCTION 
Malaria is a protozoan disease transmitted by the bite of infected Anopheles mosquitoes. Transmission by a 
transfusion of parasite infected blood and transplacental transmission are also possible (White NJ et al., 2009). 
 Malaria remains a major global problem, exacting an unacceptable toll on the health and economic 
welfare of the world’s poorest communities. There were an estimated 247 million malaria cases, (189–327 
million) worldwide, of which the vast majority of cases (86%) were in the African Region. There were an 
estimated 881, 000 (610,000–1, 212, 000) deaths worldwide, of which 90% were in the African Region (WHO, 
2008).  
In Ethiopia, malaria is ranked as the leading communicable disease accounting for about 30% of the 
overall disability adjusted life years lost (mop EFY, 2010). In 2007/2008, malaria was the first cause of 
outpatient visits, health facility admissions and in-patient deaths, accounting for 12% of out-patient visits and 
9.9% of admissions (Daddi J et al., 2010). 
Plasmodium vivax is neither rare nor benign. It occurs throughout the tropics, except in western and 
central sub-Saharan Africa. It is the most geographically widespread and the second prevalent cause of malaria 
globally. About 10–20% of the global burden of p.vivax malaria occurs in Africa, especially in Eastern and 
Southern African countries. In Ethiopia, P. vivax malaria accounts for 40% of whole malarial case (Price NR et 
al., 2007 and EFMOH, 2004). 
Early treatment is important to prevent severe illness and death due to malaria. Currently, chloroquine 
has been used as first-line drug for treatment of P. vivax infection throughout the Ethiopia as well as most part of 
the world. Historically, chloroquine clears fever and parasitemia caused by P. vivax within, at most, 72 h of the 
first dose. The drug is very rapidly absorbed and slowly eliminated, principally as a parent drug and a desethyl 
metabolite in roughly 3:1 proportions. The plasma half-life is about 50 h, and therapeutic levels against p.vivax 
malaria persist in blood until about days 21 to 35 after the start of treatment (EFMOH, 2004 and Rosenthal PJ et 
al., 2008).  
Emerging resistance to chloroquine (CQ) by p.vivax malaria threatens the health of the hundreds of 
millions of people routinely exposed to the risk of infection with this organism. Resistance by P. vivax was 
unknown until 1989, when Australians repatriated from Papua New Guinea failed routine treatment (Baird JK et 
al., 2004). Since then there were many reports and researches confirming the resistance of P.vivax to chloroquine. 
In Ethiopia there was a report of failure alarm for chloroquine 14 years back. In 2003 a study in 
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Debrezeit and Nazareth, Ethiopia showed four treatment failures among 135 patients who completed 28 days 
follow up period in CQ treated group without determining plasma drug concentration (Asnakew KY et al., 2010). 
In year 2006 another in vivo drug efficacy study conducted in Debre Zeit, Ethiopia, showed 4.6% cumulative 
incidence of therapeutic failure within 28 days of follow up period for standard directly supervised dose of 
chloroquine therapy (Hiwot T et al., 2008). More recently, a similar study conducted in Serbo town, Jimma zone, 
Ethiopia showed 3.6% therapeutic failures (Tsige K et al., 2009). However, such efficacy study is totally absent 
in jimma town despite of being one of major malarious site of the country.  Therefore, as aimed to assess the 
therapeutic efficacy of chloroquine against P.vivax malaria at public health facilities in Jimma Town, this study 
revealed 2.7% treatment failure.  
 
METHODS 
Study area and period 
The study was conducted in Jimma town at two health centers from February 10 to May 09, 2011. Jimma town is 
located 350Km south-west of Addis Ababa.  The town’s geographical coordinates are approximately 7°41’ N 
latitude and 36° 50’E longitude. The town is found in an area of average altitude of about 1780 m above sea 
level. It lies in the climatic zone locally known as Woyna Daga which is considered ideal for agriculture as well 
as human settlement. The town is generally characterized by warm climate with a mean annual maximum 
temperature of 30°C and a mean annual minimum temperature of 14°C. The annual rainfall ranges from 1138 
mm to 1690 mm.The town had the total population of 120,600 in 2007 population census and the majority of the 
population is Oromo by ethnicity. Jimma town comprised of one governmental specialized hospital, three health 
centers and nongovernmental many private clinics, pharmacies, drug stores and drug venders. 
Study design 
The study design was one-arm prospective evaluation of clinical and parasitological responses of directly 
observed chloroquine treatment of uncomplicated p.vivax malaria per WHO 2009 protocol. 
Study participants 
Suspected patients seeking medication in Jimma Health Centers were examined for the presence of P. vivax 
parasite monoinfection, on thick and thin film preparations, witha threshold of 250 parasites/µl or above. Among 
the screened patients, those who fulfilled inclusion criteria set by WHO (WHO 2009) were recruited for the 28-
days in vivo study. 
The sample size was calculated based on the expected proportion of P. vivax treatment failures with 
CQ in the study population as recommended by WHO protocol 2009 (WHO 2009) on assessing antimalarial 
drug efficacy and safety. Assuming a maximum of 4.6% treatment failure in the population, at a confidence level 
of 95% and margin of sampling error tolerated 5%, minimum sample sizes was 67 and with 20% increase to 
allow loss to follow-up and withdrawals during the 28 day follow-up period, a total of 81 study participants were 
enrolled using Quota sampling technique.  
Data collection procedure 
Treatment and follow-up 
Patients with uncomplicated P.vivax malaria, who met the inclusion criteria were enrolled, treated on site with 
Chloroquine (10mg/kg at 0 and 24 hrs followed by 5mg/kg at 48 hrs orally) and monitored for 28 days. 
Clinical evaluation 
All patients were evaluated clinically by health officers.Physical examination were performed at the baseline 
(day 0 before dosing) and on days 1, 2, 3, 7, 14, 21, and 28. A demographic information and contact details, 
complete medical history including malaria signs and symptoms and medication history were screened at 
baseline in outpatient department. Medical and medication history were being assessed continuously on each 
patient visit.Body weight was recorded on day 0 to calculate the dose of drug to be administered. Axillary 
temperature was measured at baseline (day 0 before dosing) and on days 1, 2, 3, 7, 14, 21 and 28. Temperature 
was measured with thermometer that has a precision of 0.1°C. 
Parasitologic investigation 
For blood collection, finger-prick blood samples were collected from consenting patients for malaria parasite 
identification by four laboratory technicians two from each health center. 
Thick and thin blood films were prepared and stained with 10% Giemsa stain for parasite counts and 
examined for screening on day 0 to confirm adherence to the inclusion and exclusion criteria. Thick blood films 
were also examined on days 2, 3, 7, 14, 21, and 28. Parasite count was based on the number of asexual parasites 
observed against 200 leukocytes. Parasite density calculated as: 
Parasite density (per µl) =   Average number of parasite counted x (6000-8000) WBCs 
Average number of leukocytes counted 
Quality assurance 
For microscopic investigation a fresh Giemsa stain dilution was prepared at least once a day. For drug qualities a 
nationally recognized source of quality drugs was used: - Chloroquine phosphate 250mg tablet equivalent to 
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150mg chloroquine, batch number 0040223, Ethiopian pharmacietical manufacturing. 
The principal investigator ensured that the study protocol was strictly adhered to and that all data were 
being collected and recorded correctly on the case report form. Laboratory and clinical data were recorded on a 
daily basis on the case report form designed for the study. The principal investigator was responsible for keeping 
all screening forms, the case report form and the completed subject identification code list in a secure location. 
After completion of data collection, data were entered into a SPSS database by double independent data entry.  
Data Analysis 
Data collected from in vivo therapeutic efficacy test was double entered and analyzed using SPSS (version 16.0). 
Descriptive statistics were used for demographic and clinical characteristics of participants at day of enrollement. 
Kaplan-Meier survival probability analysis was used to evaluate treatment outcome of study participants during 
follow-up period. The proportion of patients who experienced therapeutic failure during the follow-up period 
was used to estimate the efficacy of study drug. Other statistics used were Pearson’s correlation for correlation 
between parasite and fever clearance time, logistic regression to test association between age; and sex and 
treatment response and Mann-Whitney u test to compare difference in geometric mean parasite between 
treatment failures and adequate clinical and parasitological responses. 
Ethical considerations 
Approval by the Jimma university ethical review committee was obtained before the study. 
Patients were included in the study only when they or guardians in the case of children gave informed 
consent. All patients’ information was remaining confidential and was shared only by the study team.  
 
RESULTS 
Patients who were febrile or had history of fever with in past 24 hours of diagnosis were sent from out patient 
department to laboratory and diagnosed for malaria. Among patients who were P.vivax positive, a total of 81 
eligible patients were enrolled. Among 81 enrolled 5 were lost to follow up, 2 were withdrown from study and 
74 were completed 28 days of follow up. Among 81 participants 60.5% were adults and 41(50.6%) were male 
(table 1).  
Among the study participants, temperature was range from 36 to 40.3°C and parasite load range from 
1200 to 15600count/ µl on the day of enrollment. Descriptive results are presented below. 
In age and sex distribution of clinical characteristics, relatively higher geometric mean parasite load 
and mean axillary temperature was recorded in underfive age group while relatively lower in middle age group 
(table 3).  
Gennerally fever and parasite clearance rate look like collinear with in first three days. Then fever 
curve maintained horizontal while geometric mean parasite was not (figure 1). 
There was 98.8% fever clearance and 93.8% parasite clearance on day 2. On day 3 there was 100% 
clearance of both parasite and fever among 79 participants who continued in the study. 
However, we did not detected any significant correlation between fever clearance time and parasite 
clearance time (Pearson correlation, r = 0.106, P = 0.347). 
According to Kaplan Meier analysis the total cumulative incidence of treatment failure was 
2.7 %( 95% CI: -0.99   -   6.39). Since exclusion from study in seven participants had ocured (on day 2 and day 3) 
before treatment failure (on day 7 and day 28) censoring for analysis does not alter the cumulative incidendence 
of treatment failure. Exclusion from study is due to self administration of antimalarial drug in two patients and 
loss to follw up in five participants. 
We did not detect a significant difference in geometric mean parasite density at enrollment between 
treatment failures (mean rank, 41.75) and successes (mean rank, 37.38; Mann-Whitney U test, P = 0.777). 
 
DISCUSION 
Chloroquine clears fever and parasitemia caused by plasmodium vivax within, at most, 72 h of the first dose. 
Historically, it was 100% effective in treatment of p.vivax (Rosenthal PJ 2008). This study revealed 97.3% 
effectiveness of the drug at the end of 28 days follow up. 
In this study, at the day of enrollement 82.7% of patients were fibrile and 98.8% cleared within 48 
hours and 100% within 72hours of the follow up. Parasite clearance rate was 93.8% on day 2 and 100% on the 
day 3. This is almost similar with a study which was conducted in Debre Zeit (Hiwot T et al., 2008), 98% 
parasite clearance on the day 3 and has higher response rate than a study which was conducted in Serbo town in 
Jimma Zone (Tsige K et al., 2009) in which parsite clearance at day 3 was 88% while fever clearance was 89.7%.  
Eventhough there was 100% clearance rate of both fever and parasitemia within 72hours of follow up; 
there was insignificant correlation between fever and parasite clearance (Pearson correlation, r = 0.106, P = 
0.347). This may indicate fever may not depend up on parasite load only but also individual variation of body 
response to the parasite may be important. The faster fever clearance rate may be due to paracetamol 
coadministration in fibrile patients.  
Journal of Health, Medicine and Nursing                                                                                                                                          www.iiste.org 




In fact medication effect differs with age and sex, but in this study both sex and age group of 
participants were insignificantly associated with parasite and fever clearance rate of chloroquine in P.vivax 
malaria (table 5). This may indicate efficacy of chloroquine in P.vivax malaria is less dependent on age and sex 
when given equivalent dose adjusted to body weight. 
 In this study, we were able to observe two late parasitological failures, in an eight years old male 
participant and 18years old female participant. The male patient on the day of enrollement had axillary 
temperature of 38.8  ͦc and 8010/µl of parasite load. Fever cleared within 48hours where parasite load decreased 
to 840count/µl on day 2 and undetectable on the day 3.  However, parasitemia reappeared on day 7 without any 
clinical symptom of malaria.  
In the 18years old female patient, on day of enrollment, she had axillary temperature of 37.6 ͦ c and 
fever was cleared within 24hours. Parasite load on enrollement was 3280count/µl and she was cleared of 
parasitemia within 48 hours. Despite fast clearance of fever and parasitemia, there was reappearance of 
parasitemia on day 28 without clinical symptom of malaria. 
In this study five participants were lost to follow up despite of every effert (two on day 2 and three on 
day 3 of follow up) and there was two withdrawals (one on day 2 and one on day 3) due to self administration of 
other antimalarial drug (COARTEMR). Therefore, two participants on day 2 and five participants on day 3 were 
excluded from study. However, treatment failure was occurred on day 7 and on day 28. In this case, censoring 
for withdrawal and lost to follow up do not affect cumulative incidence of treatment failure. Therfore, our 
cumulative incidence of treatment failure was 2.7%.  
The similar studies which were conducted in Debre Zeit and Serbo town in Jimma Zone, Ethiopia, 
were revealed hardly lower response rate. In Debre Zeit the cumulative incidence of resistance was 4.6% and in 
Serbo town it was 3.6%. Higher response rate in our study than in Debre Zeit and Serbo Town does not implay 
increasing sensitivity because study sites are different .i.e. resistance is different in different catchment areas. 
Despite of a little difference in response rate in our study and above two studies, the failures were late 
parasitological (Hiwot T et al., 2008, Tsige K et al., 2009). Similar study result from Madagaskar (Barnadas C et 
al., 2008), showed higher failure rate. There was 10.2% recurrence and after genotyping correction, five cases 
(5.1%) of recurrence were confirmed as resistance. 
Eventhough there was relatively high parasite load at day of enrollement (Day 0) in treatment failures; 
we did not detect a significant difference in geometric mean parasite density at enrollment between treatment 
failures and successes in Mann-Whitney, P = 0.777).  Despite of different test statistics, this result was in 
agreement with a study in Debre Zeit (21) (p=0.061). A similar study in the eastern Indonesia (Sutanto et al., 
2009) showed similar result (P = 0.341). This may indicate recurrence of parasitemia after standard treatment 
less probably dependas up on parasite load before treatment.  
Recurrence parasitemia may be due to different reasons; recrudence, reinfection or reactivation of liver 
hypnozoit of plasmodium. The day 7 recurrences is most probably resistance strain and less probably reinfection 
or relapse, because plasma therapeutic concentration sustains more than 21 day after three day standard dosage 
of chloroquine. Even if it is reinfection or relapse, it is most probably resistance strain. However, our study lacks 
test of therapeutic level of chloroquine in the blood to say so.  Recurrence on day 28 may be due to any of above 
mentioned reasons which can only be determined genotyping in addition to blood drug concentration. 
Ufortunately, our study suffers limitation of unavailability of genotyping of P.vivax species. 
 
CONCLUSSIONS 
In general, this study revealed good clinical and parasitological response of plasmodium vivax to chloroquine. 
Our study also showed fast clearance of fever and parasitemia within maximum of 72hours of start of medication. 
Therefore, chloroquine can be continued as 1st line medication for the P.vivax malaria in the study area.  
However, reappearance of the parasite within the 28 days of follow-up in the study area signals the need for 
launching monitory activities for Chloroquine resistant by the P. vivax parasite. 
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Table I. Age and sex of the study participants on the day of enrollement, Jimma town, southwest Ethiopia, 2011 
Characteristics Value at day of admission (Day 0) 
Age groups (years) 
 
 








Table II Clinical characteristics of the study participants on the day of enrollement, Jimma town, southwest 
Ethiopia; 2011 
Characteristics Value at day of admission (Day 0) 
Mean Body Temp. in   °C ± SD 38.00 (±0.86) 
Febrile (Axillary Temp. ≥ 37°C) (No/%) 67 (82.7%) 
History of Fever (No. / %) 79 (97.5%) 
Geometric mean parasite/µl  ± SD 5276 (±3257)      
 




sex Mean body 
Temp.(°C) 
Febrile (Axillary 
Temp. >37°C) /% 
History of Fever within 
past 24hrs /% 
Geometric mean 
parasite/µl 
<5 M  38.4 100 100 5750 
F  37.4 60 100 6566 
5-14 M 37.9 81.2 93.7 5158 
F  37.4 66.7 100 3680 
>14 M  38.2 91.3 95.5 4892 
F  38.0 92.3 100 5957 
All age 
group 
M  38.1 87.8 95.1 5037 
F  37.8 82.5 100 5521 
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Figure I. General trend of fever and parasitic load clearances in the study participants in Jimma town, Southwest  
 
Table IV. Aassociation between demographic characteristics and treatment response, Jimma town, Southwest 
Ethiopia, 2011 
                                              for fever clearance  
Age and sex  P value  OR             95% CI of OR  
5  0.999  0.000 0.000     +∞  
5-14  0.921  1.100 0.166  7.303  
>14  1.00   
female  0.244  0.261 0.027  2.506  
Male   1.00   
                                            For parasite clearance 
5  0.206  5.726  0.383  85.567  
5-14  0.629  1.659  0.213  12.936  
>14  1.00   
female  0.181  0.199  0.019  2.119  
Male   1.00   
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Table V. Treatment outcome of study participants versus days of follow up, in Jimma town, Southwest Ethiopia, 
2011 
 
Follow-up     PR             W       TF         II           CITF                         95% CI  
   Days                                                                                           ……………………. 
                                                                                                         LL                   UL                                                                                                                                     
Day 0             81             0         __        __            ___                   _____                ___ 
Day 1             81             0         0           0              0                          -                   - 
Day 2             81             2         0           0              0                          -                   - 
Day 3             79             5         0           0              0                          -                   - 
Day 7             74             0         1       0.0135       0.0135                   -1.63    -     3.98                 
Day 14           73             0         0           0            0.0135                   -1.63    -     3.98                 
Day 21           73             0         0           0            0.0135                   -1.63    -     3.98                 
Day 28           73             0         1       0.0135       0.0270                    -0.99   -      6.39 
PR=Population at risk, W=Excluded from the study (2 withdrawal and 5 loss to follow up), TF= Treatment 
failure, II=interval incidence, CI=confidence interval, LL=Lower limit, UL=Upper limit, Confidence interval 
describes range of probability under which cumulative incidence of treatment failure may fall. 
 
